62.45 USD
↘ 0.31 (0.49%)AT CLOSE (11:59 AM EDT)
Travere Therapeutics, Inc. Common Stock
TVTXNASDAQ • USD
62.54
↗ 0.09 (0.14%)
POST MARKET (AS OF 07:34 PM EDT)
Post Market
AS OF 07:34 PM EDT
62.54
↗ 0.09 (0.14%)
Market: CLOSED
Travere Therapeutics, Inc. Common Stock (TVTX) trades at $62.45 per share. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, TVTX trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Aug 6, 2026.
Open?$63.69
High?$65.45
Low?$62.10
Prev. Close?$62.76
Volume?2.9M
Avg. Volume?1.8M
VWAP?$63.52
Rel. Volume?1.62x
Bid / Ask
Bid?$53.41 × 100
Ask?$71.44 × 100
Spread?$18.03
Midpoint?$62.43
Valuation & Ratios
Market Cap?5.9B
Shares Out?93.0M
Float?88.9M
Float %?95.6%
P/E Ratio?N/A
P/B Ratio?241.25
EPS?-$0.46
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Themes
Address
3611 VALLEY CENTRE DR
SAN DIEGO, CA 92130
Phone: 888-969-7879
SAN DIEGO, CA 92130
Phone: 888-969-7879
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?75
Momentum?57
Short Sent.?39
Piotroski F-Score?3/9Weak
Altman Z-Score?3.14Safe
Confidence?66%Moderate
Short InterestHigh
Short % of Float?13.51%High
Short Interest?12.0M
Days to Cover?9.2
Free Float88.9M
Avg Daily Volume1.3M
Settlement Date2026-07-15
Financial Health
Current Ratio?4.05Strong
Quick Ratio?3.99Strong
Cash Ratio?0.77Adequate
Debt/Equity?24.58High
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score33/100
P/E?N/A▾
P/B?241.25HIGH▾
Peers100
S&P3
P/S?10.00HIGH▾
Peers100
S&P8
P/FCF?63.9PRICEY▾
Peers100
S&P6
EV/EBITDA?279.4HIGH▾
Peers100
S&P3
EV/Sales?10.82HIGH▾
Peers100
S&P9
Returns & Efficiency
ROE?-177.2%WEAK▾
S&P3
ROA?-5.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$92.6M
Enterprise Value?$6.4B
Fundamentals ratios updated end of day